Amgen, Inc. (NASDAQ:AMGN) and Array Biopharma Inc (NASDAQ:ARRAY) have announced today the partnership agreement as an effort to discover and develop new drugs for autoimmune diseases. The unrevealed target and lead inhibitors were found out through the Array’s proprietary podium that leverages its capability in chemistry and early development.
Array Biopharma made a deal with the industry giant to manufacture drugs for the autoimmune disorders that have become complex in the recent past years. The collaboration will enable the two companies to advance the studies on molecules into their clinics so as to provide new treatment alternatives for patients.
Amgen is a leading company in the treatment of inflammatory diseases and the new deal could help Array develop an effective drug that will significantly address the existing gaps in the medical field. The agreement terms state that the two companies will join forces in preclinical development as Array leads the chemistry medicinal work.
Also, Amgen will carry out both the clinical development and commercialization. Amgen will, therefore, make both upfront and milestone payments as well as the royalties payments. According to the chief scientific officer at Array Nicholas Saccomano, the new target together with their capable team in kinase inhibitor chemistry will enable them to obtain a drug that will relieve patients suffering from the inflammatory disease.
The partnership will help the two firms to team up their resources to develop the much-awaited drug. In May, Array partnered with another pharmaceutical giant known as Bristol-Myres Squibb to carry out clinical tests to the efficiency of Array’s binimetinib drug by combining it with Bristol-Myers’ drug in order to treat colorectal cancer.
It’s hoped that the findings will be a major milestone in managing the inflammation disorders. With more than 20 years of experience in the pharmaceutical industry, Amgen brings its knowledge, skills, and expertise needed to help in discovering the right drug for the autoimmune illnesses. The new agreement builds on Amgen’s continued focus in the inflammation, which is one of the company’s critical areas of interest.